Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology

Journal: J Thorac Dis.
Veröffentlichung: 2019 Jan

2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer

Journal: J Thorac Oncol.
Veröffentlichung: 2019 Feb 11

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Journal: J Thorac Oncol.
Veröffentlichung: 2018 Dec 31

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies

Journal: Mod Pathol.
Veröffentlichung: 2018 Nov 20

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Journal: Nat Commun.
Veröffentlichung: 2018 Nov 7

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Journal: Ann Oncol.
Veröffentlichung: 2018 Oct 1

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)

Journal: Clinical Cancer Research
Veröffentlichung: 2018 Jul 1

Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC; a central role of TP53 mutations

Journal: The Journal of Pathology
Veröffentlichung: 2018 Sep

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Journal: Annals of oncology
Veröffentlichung: 2018 Jun 1

Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer

Journal: Cancer Research
Veröffentlichung: 2018 Mai 18

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients

Journal: Clinical Cancer Research
Veröffentlichung: 2018 Mar 15

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

Journal: Nature Communications
Veröffentlichung: 2018 Mar 13

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance

Journal: Oncotarget.
Veröffentlichung: 2018 Mar 8

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Journal: Histopathology
Veröffentlichung: 2018 Feb

Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer

Journal: Strahlenther Onkol.
Veröffentlichung: 2018 Feb

Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer

Journal: Clinical Cancer Research
Veröffentlichung: 2017 Sep 15

LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells

Journal: Scientific Reports
Veröffentlichung: 2017 Aug 31

Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center

Journal: Lung Cancer
Veröffentlichung: 2017 Jun

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

Journal: JAMA
Veröffentlichung: 2017 Mai 9

ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor

Journal: NPJ Precis Oncology
Veröffentlichung: 2017 Mar 20

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Journal: Lancet
Veröffentlichung: 2017 Jan 23

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Journal: J Clin Oncol.
Veröffentlichung: 2017 Jan 10

ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.).

Journal: Lung Cancer
Veröffentlichung: 2017 Jan

Stratified Treatment in Lung Cancer

Journal: Onol Res Treat
Veröffentlichung: 2016 Nov 24

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors.

Journal: Clin Cancer Res.
Veröffentlichung: 1. Oktober 2016

ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology.

Journal: Ann Oncol.
Veröffentlichung: 27. September 2016

Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a TP53 Context-specific Manner.

Journal: Mol Cancer Res.
Veröffentlichung: 2016 Aug 11

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. oncology.

Journal: Pathologe
Veröffentlichung: 2016 Aug 10

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

Journal: Mod Pathol
Veröffentlichung: 8. Juli 2016

137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses.

Journal: J Thorac Oncol
Veröffentlichung: 11. April 2016

ALK-Diagnostics in NSCLC – Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)

Journal: Pneumologie
Veröffentlichung: 01. April 2016

PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.

Journal: Oncoimmunology
Veröffentlichung: 16. März 2016

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Journal: Lancet Oncol.
Veröffentlichung: 06. März 2016

Clinicopathological characteristics of RET rearranged lung cancer in European patients

Journal: IASLC
Veröffentlichung: 11.01.2016

Developments in oncological positron emission tomography/computed tomography assessment

Journal: J Thorac Dis
Veröffentlichung: 7. Dezember 2015

Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases

Journal: Exp Mol Pathol
Veröffentlichung: 6. November 2015

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

Journal: Oncologist
Veröffentlichung: 20. Oktober 2015

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.

Journal: J Thorac Oncol.
Veröffentlichung: 10. Oktober 2015

NOTCH, ASCL1, p53 und RB Änderungen definieren einen alternativen Weg Fahr neuroendokrinen und kleinzelligen Lungenkarzinomen.

Journal: Int J. Cancer
Veröffentlichung: 4. September 2015

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.

Journal: AAPS J.
Veröffentlichung: 19. August 2015

Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.

Journal: Eur J Nucl Med Mol Imaging
Veröffentlichung: 18. Aug. 2015

Comprehensive genomic profiles of small cell lung cancer.

Journal: Nature
Veröffentlichung: 6. Aug. 2015

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

Journal: J Thorac Oncol
Veröffentlichung: Jul. 2015

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

Journal: Cell
Veröffentlichung: 2. Juli 2015

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

Journal: J Thorac Oncol
Veröffentlichung: 10. Jun. 2015

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Journal: Oncotarget
Veröffentlichung: 30. Apr. 2015

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.

Journal: J. Clin Oncol
Veröffentlichung: 20. März 2015

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Journal: Lancet Oncol
Veröffentlichung: 16. März 2015

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus.

Journal: Lung Cancer
Veröffentlichung: Feb. 2015

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Journal: Oncotarget
Veröffentlichung: 20. Jan. 2015

PD-L1 expression in small cell neuroendocrine carcinomas.

Journal: Eur J Cancer
Veröffentlichung: 9. Jan. 2015

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data.

Journal: Genome Biol.
Veröffentlichung: 5. Jan. 2015

MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

Journal: Clin Cancer Res.
Veröffentlichung: 2015 Februar 15

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy

Journal: Lancet Respir Med
Veröffentlichung: 2. Dezember 2014

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer

Journal: Int J Radiat Oncol Biol Phys
Veröffentlicht: 1. Dezember 2014

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Journal: Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667.Epub 2014Aug 31
Veröffentlichung: 20. September 2014 (Epub 31. August 2014)

Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib

Journal: J Thorac Oncol
Veröffentlichung: 12. September 2014 (Epub ahead of print)

CD74-NRG1 Fusions in Lung Adenocarcinoma

Journal: Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. PMID: 24469108
Veröffentlichung: 4. April 2014 (Epub 27. Januar 2014)

Ceritinib in ALK-rearranged non-small-cell lung cancer

Journal: N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107. PMID: 24670165
Veröffentlichung: 27. März 2014

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

Journal: Nat Commun. 2014 Mar 27;5:3518. doi: 10.1038/ncomms4518. PMID: 24670920
Veröffentlichung: 27. März 2014

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer

Journal: Cancer Discov. 2014 Feb;4(2):246-57. doi: 10.1158/2159-8290.CD-13-0323. PMID: 24302556
Veröffentlichung: 4. Februar 2014 (Epub 3. Dezember 2014)

A Genomics-Based Classification of Human Lung Tumors

Journal: The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM), Science Translational Medicine, October 2013. doi: 10.1126/scitranslmed.3006802
Veröffentlichung: Oktober 2013

Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small.cell lung cancer

Journal: Modern Pathology, July 2013. doi:10.1038/modpathol.2013.141
Veröffentlichung: Juli 2013

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

Journal: Lung Cancer, Vol 81, No 1, July 2013. doi:10.1016/j.lungcan.2013.02.018
Veröffentlichung: Juli 2013

Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment

Journal: Journal of Clinical Oncology, Vol 15, No 15, May 2013, doi:10.1200/jco.2012.45.9867
Veröffentlichung: Mai 2013

FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications

Journal: Translational lung cancer research, Vol 2, No 2, April 2013, doi:10.3978/j.issn.2218-6751.2013.03.03
Veröffentlichung: April 2013

Activated RET and ROS: two new driver mutations in lung adenocarcinoma

Journal: Translational lung cancer research, Vol 2, No 2, April 2013. doi: 10.3978/j.issn.2218-6751.2013.03.08
Veröffentlichung: April 2013

Tumor VEGFR:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer

Journal: Journal of Clinical Investigation, Vol 123, No 4, April 2013, doi:10.1172/JCI65385
Veröffentlichung: April 2013

Molecular pathology of the lungs. New perspectives by next generation sequencing

Journal: Der Pathologe, Vol 34, No 1, February 2013. doi: 10.1007/s00292-012-1704-7
Veröffentlichung: Februar 2013

Lung Cancer: Molecular pathology and personalized therapy

Journal: Der Internist, Vol 54, No 2, February 2013. doi: 10.1007/s00108-012-3151-1
Veröffentlichung: Februar 2013

Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

Journal: PLoS One, Vol 8, No 1, January 2013. doi 10.1371/journal.pone.0053081
Veröffentlichung: Januar 2013

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models

Journal: Clinical Cancer Research, Vol 18, No 24, December 2012, doi: 10.1158/1078-0432.CCR-12-2694
Veröffentlichung: Dezember 2012

Genetic insight and therapeutic targets in squamous-cell lung cancer

Journal: Oncogene, Vol 31, No 46, November 2012, doi: 10.1038/onc.2011.640
Veröffentlichung: November 2012

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Journal: Nature Genetics,Vol 44, No 10, October 2012. doi: 10.1038/ng.2396
Veröffentlichung: Oktober 2012

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

Journal: Proc Natl Acad Sci USA, Vol 109, No 42, October 2012, doi: 10.1073/pnas.1207310109
Veröffentlichung: Oktober 2012

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET

Journal: Lung Cancer, Vol 77, No 3, September 2012, doi: 10.1016/j.lungcan.2012.05.110
Veröffentlichung: September 2012

Indications and limitations of fresh frozen sections in the pulmonary apparatus

Journal: Der Pathologe, Vol 33, No 5, September 2012, doi: 10.1007/s00292-012-1603-y
Veröffentlichung: September 2012

Comprehensive genomic characterization of squamous cell lung cancers

Journal: Nature, Vol 489, No 7417, September 2012, doi: 10.1038/nature11404
Veröffentlichung: September 2012

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Journal: Cell, Vol 150, No 6, September 2012, doi: 10.1016/j.cell.2012.08.029
Veröffentlichung: September 2012

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Journal: Clinical Cancer Research, Vol 18, No 17, September 2012, doi: 10.1158/1078-0432.CCR-11-3260
Veröffentlichung: September 2012

Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer

Journal: Journal of Clinical Oncology, Vol 30, No 27, September 2012, doi: 10.1200/JCO.2012.43.1825
Veröffentlichung: September 2012

Early palliative care for patients with metastatic cancer

Journal: Current Opinion in Oncology, Vol 24, No 4, July 2012, doi:10.1097/CCO.0b013e328352ea20
Veröffentlichung: Juli 2012

Predictive value of early and late 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

Journal: European Journal of Nuclear Medicine & Molecular Imaging, Vol 39, No 7, July 2012, doi: 10.1007/s00259-012-2118-8
Veröffentlichung: Juli 2012

Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation in Patients With Advanced Non–Small Cell Lung Cancer Treated With Erlotinib

Journal: Clinical Nuclear Medicine. Vol 37, No 11, doi: 10.1097/RLU.0b013e3182639747
Veröffentlichung: 2012

Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities

Journal: Clinical Cancer Research, Vol 18, No 9, May 2012 May, doi: 10.1158/1078-0432.CCR-11-2370
Veröffentlichung: Mai 2012

Recommending early integration of palliative care – does it work?

Journal: Support Care Cancer, Vol 20, No 3, March 2012, doi: 10.1007/s00520-011-1111-2
Veröffentlichung: März 2012

Personalized therapy of lung cancer

Journal: Onkologie, Vol 35, No 1, February 2012, doi: 10.1159/000334827
Veröffentlichung: Februar 2012

The association between active participation in a sports club, physical activity and social network on the development of lung cancer in smokers: a case-control study

Journal: BMC Research Notes, Vol 5, No 2, January 2012 doi: 10.1186/1756-0500-5-2
Veröffentlichung: Januar 2012

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

Journal: Clinical Cancer Research. Vol 17, No 23, December 2011, doi: 10.1158/1078-0432.CCR-11-1648
Veröffentlichung: Dezember 2011

Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model

Journal: Journal of Thoracic Oncology, Vol 6, No 12, December 2011, doi: 10.1097/JTO.0b013e3182307ede
Veröffentlichung: Dezember 2011

Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET

Journal: Journal of Nuclear Medicine, Vol 52, No 12, December 2011, doi:10.2967/jnumed.111.094458
Veröffentlichung: Dezember 2011

A crucial requirement for Hedgehog signaling in small cell lung cancer

Journal: Nature Medicine, Vol 17, No 11, October 2011, doi: 10.1038/nm.2473
Veröffentlichung: Oktober 2011

Personalized therapy of lung cancer cokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

Journal: Clinical Pharmacokinetics, Vol 50, No 9, September 2011 doi: 10.2165/11593320-000000000-00000
Veröffentlichung: September 2011

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

Journal: Cancer Research, Vol 71, No 14, July 2011, doi: 10.1158/0008-5472.CAN-10-3879
Veröffentlichung: Juli 2011

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

Journal: Cancer Discovery, Vol 1, No1, June 2011, doi: 10.1158/2159-8274.CD-11-0005
Veröffentlichung: Juni 2011

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines

Journal: Clinical pharmacokinetics, Vol 50, No 6, June 2011. doi: 10.2165/11587020-000000000-00000
Veröffentlichung: Juni 2011

Blood-based gene expression signatures for early detection of lung cancer

Journal: Clinical Cancer Research, Vol 17, No 10, May 2011, doi: 10.1158/1078-0432.CCR-10-0533
Veröffentlichung: Mai 2011

Benchmarking of mutation diagnostics in clinical lung cancer specimens

Journal: PLoS One, Vol 6, No5, May 2011, doi: 10.1371/journal.pone.0019601
Veröffentlichung: Mai 2011

Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography

Journal: Journal of Clinical Oncology, Vol 29, No 13, May 2011, doi: 10.1200/JCO.2010.32.4939
Veröffentlichung: Mai 2011

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL)

Journal: Journal of Clinical Oncology, Vol 29, No 8, March 2011, doi: 10.1200/JCO.2010.29.5717
Veröffentlichung: März 2011

Molecular diagnostics of lung cancer for treatment stratification

Journal: Der Internist Vol 52, No 2, February 2012, doi: 10.1007/s00108-010-2698-y
Veröffentlichung: Februar 2011

Focal amplification of FGFR1 associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer

Journal: Science Translational Medicine, Vol 2, No 62, December 2010, doi: 10.1126/scitranslmed.3001451
Veröffentlichung: Dezember 2010

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

Journal: Nucleic Acids Research, Vol 38, No 20, November 2010, doi: 10.1093/nar/gkq579
Veröffentlichung: November 2010

Cytohesins Are Cytoplasmic ErbB Receptor Activators

Journal: Cell, Vol 143, No 2, October 2010, doi: 10.1016/j.cell.2010.09.011
Veröffentlichung: Oktober 2010

Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium

Journal: Journal of the National Cancer Institute
Veröffentlichung: 2010 Jul 07

Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility project

Journal: Journal of palliative medicine
Veröffentlichung: Juni 2010

Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor

Journal: Journal of Medicinal Chemistry
Veröffentlichung: 2010 April 08

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors

Journal: Journal of Thoracic Oncology
Veröffentlichung: März 2010

Identification of lung cancer with high sensitivity and specificity by blood testing

Journal: Respiratory Research
Veröffentlichung: 2010 Feb 10

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

Journal: Cancer Research
Veröffentlichung: 2010 Feb 01

Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling

Journal: PLoS One
Veröffentlichung: 2010 Jan 27

Molekulare Diagnostik

Das Netzwerk Genomische Medizin bietet eine umfassende molekulare Analyse von Tumorproben an. Mittels eines Next Generation Sequencing basierten Multiplex-Verfahrens werden sämtliche therapierelevanten genomischen Veränderungen auch in kleinsten Gewebeproben zuverlässig detektiert.


Haben Sie Fragen zu Ihrer Erkrankung, Ihrer bestehenden Therapie oder vielleicht möchten Sie auch wissen, ob für Sie ein personalisierter Therapieansatz oder eine Immuntherapie in Frage kommt?

Kontaktieren Sie uns!

Klinische Studien

Innerhalb des Netzwerks Genomische Medizin wollen wir allen Patienten mit einer Mutation, für die es noch kein zugelassenes Medikament gibt, eine klinische Studie anbieten.

Informieren Sie sich hier, welche aktuellen Studien es gibt.